Pinnacle to expand European sales force with pharmexx

Pinnacle Biologics, a private, USA-based, full-service pharmaceutical and biotechnology solutions company, has entered into an agreement with pharmexx to expand sales support activities in a number of countries in western Europe.

Terms of the deal were not disclosed, but Viren Grover, vice chairman of Pinnacle, said "we are pleased to conclude this agreement with pharmexx, which allows us a cost-effective way to support our sales and marketing activities for Ethyol (amifostine) in key European markets where we believe there is upside potential." The injectable cancer drug earned $80.0 million in the USA last year.

According to Pinnacle, pharmexx is one of the leading contract sales organizations worldwide. The firm provides pharmaceutical and biotechnology companies with marketing and sales solutions, as well as its own sales teams.